Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216322 | 1.00 | MEN1 (0.55) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL2230223 | 1.00 | MEN1 (0.55) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1334464 | 0.90 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1334462 | 0.90 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1335011 | 0.90 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL25513795 | 0.87 | HPGD (0.60) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL2927661 | 0.87 | HPGD (0.60) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL18549298 | 0.82 | NR1H2 (0.54) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL970631 | 0.82 | NR1H2 (0.54) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL12908 | 0.81 | ALDH1A1 (0.56) | MEN1ALDH1A1MAPTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735433-A2 | SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF | Viva Star Biosciences (US) Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4656249-A2 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025006681-A2 | SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF | VIVA STAR BIOSCIENCES (US) INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-3478687-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2024-03-20 | — | — | EP | disclosed |
| CN-111542516-B | IRAK4 inhibitors and uses thereof | 新标立亚医疗有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3950691-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2022-02-09 | — | — | EP | disclosed |
| CN-107033097-B | Oxadiazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-10-08 | — | — | US | disclosed |
| US-8624033-B2 | Pleuromutilins and process for the preparation of pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2014-01-07 | — | — | US | disclosed |
| US-20130053571-A1 | PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2013-02-28 | — | — | US | disclosed |
| US-8334389-B2 | Process for the preparation of pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2012-12-18 | — | — | US | disclosed |
| EP-2069301-B1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2011-09-07 | — | — | EP | disclosed |
| EP-2272829-A2 | Process for the preparation of pleuromutilins | Nabriva Therapeutics AG (AT) | 2011-01-12 | — | — | EP | disclosed |
| US-20090253748-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2009-10-08 | — | — | US | disclosed |
| EP-2069301-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | Nabriva Therapeutics Forschungs GmbH (AT) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008040043-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2008-04-10 | — | — | WO | disclosed |
| EP-1908750-A1 | Process for the preparation of pleuromutilins | Nabriva Therapeutics Forschungs GmbH (AT) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317673-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | MAP3K5, MAP3K2, MAPKAPK5 | MEN1 3215/4885ALDH1A1 1963/4885MAPT 2758/4885 |
| US-20130053571-A1 | PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | PLEC, MLN, PTMA | MEN1 1347/4885ALDH1A1 312/4885MAPT 2481/4885 |
| US-20090253748-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | PLEC, MLN, PTMA | MEN1 1392/4885ALDH1A1 182/4885MAPT 2532/4885 |
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | MAP3K5, MAP3K2, MAPKAPK5 | MEN1 3215/4885ALDH1A1 1963/4885MAPT 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.